CMS certification 220086
Beth Israel Deaconess Medical Center
330 Brookline Avenue, Boston, MA 02215
Beth Israel Deaconess Medical Center has a CMS overall rating of 3 out of 5 stars. 79% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 7 and worse on 5. Emergency patients spend a median of 5 h 36 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 5,505 completed surveys, 25% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | MA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 361 visits sampled · US median for EDs of the same volume: 3 h 22 min | 5 h 36 min | 3 h 34 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 24 visits sampled | 5 h 14 min | 5 h 38 min | 4 h 17 min |
| Left before being seen Lower is better · 56,125 patients | 2% | 4% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 94 patients | 43% | 56% | 65% |
How Beth Israel Deaconess Medical Center compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Beth Israel Deaconess Medical CenterThis hospital | 3/5 | 79% | 5 h 36 min | 7 better 5 worse |
| New England Baptist HospitalSame city | 5/5 | 86% | — | 2 better 1 worse |
| Boston Medical CenterSame city | 3/5 | 73% | 3 h 47 min | 4 better 1 worse |
| Brigham and Women's HospitalSame city | 5/5 | 81% | 5 h | 8 better 2 worse |
| Massachusetts Eye and Ear InfirmarySame city | Not rated | 83% | 2 h 54 min | No different |
| Massachusetts General HospitalSame city | 5/5 | 85% | 4 h 48 min | 15 better 4 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Boston.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 6,560 cases | Too few cases | 2.6% | 3.9% |
| Heart attack 366 cases | Too few cases | 11.3% | 11.9% |
| Heart failure 964 cases | Too few cases | 6.9% | 11.1% |
| Pneumonia 620 cases | Too few cases | 11% | 15.2% |
| Stroke 554 cases | Too few cases | 10.3% | 11.9% |
| COPD 170 cases | Too few cases | 6.7% | 8.6% |
| Heart bypass surgery (CABG) 342 cases | Too few cases | 2.3% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.03 likely 0.85 – 1.2 | 1 |
| After hip or knee replacement 252 cases | Too few cases | 4.5% | 4.1% |
| Deaths after a serious but treatable surgical complication 432 cases | No different | 182.52 per 1,000 likely 157.03 per 1,000 – 208.01 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 16,829 cases | No different | 0.84 per 1,000 likely 0.49 per 1,000 – 1.19 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 17,760 cases | No different | 0.19 per 1,000 likely 0.04 per 1,000 – 0.33 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 18,937 cases | No different | 0.27 per 1,000 likely 0.11 per 1,000 – 0.43 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 5,770 cases | Worse | 3.94 per 1,000 likely 2.98 per 1,000 – 4.91 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 3,059 cases | No different | 1.53 per 1,000 likely 0.47 per 1,000 – 2.6 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 2,892 cases | No different | 6.37 per 1,000 likely 3.07 per 1,000 – 9.67 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 6,442 cases | No different | 3.73 per 1,000 likely 2.48 per 1,000 – 4.99 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 3,016 cases | No different | 6.05 per 1,000 likely 3.85 per 1,000 – 8.26 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 1,427 cases | No different | 1.33 per 1,000 likely 0.11 per 1,000 – 2.54 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 4,681 cases | No different | 1.07 per 1,000 likely 0.4 per 1,000 – 1.74 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.55 likely 0.36 – 0.81 | 1 |
| Urinary tract infections from catheters (CAUTI) | No different | 0.88 likely 0.58 – 1.3 | 1 |
| Surgical site infections after colon surgery | No different | 1.15 likely 0.69 – 1.8 | 1 |
| Surgical site infections after abdominal hysterectomy | Worse | 3.75 likely 1.83 – 6.89 | 1 |
| MRSA bloodstream infections | Better | 0.59 likely 0.34 – 0.97 | 1 |
| C. diff intestinal infections | Better | 0.57 likely 0.45 – 0.71 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 629 cases | Too few cases | 15.3% | 14.4% |
| Readmitted after heart failure 1,411 cases | Too few cases | 20.9% | 21.3% |
| Readmitted after pneumonia 767 cases | Too few cases | 17.1% | 17.3% |
| Readmitted after COPD 239 cases | Too few cases | 19.1% | 20% |
| Readmitted after heart bypass surgery 233 cases | Too few cases | 11.2% | 11% |
| Readmitted after hip or knee replacement 245 cases | Too few cases | 6.7% | 5.8% |
| Days back in hospital after a heart attack 583 cases | Too few cases | 25.9 days per 100 | — |
| Days back in hospital after heart failure 1,235 cases | Too few cases | 30.3 days per 100 | — |
| Days back in hospital after pneumonia 673 cases | Too few cases | 7.3 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 5,120 cases | No different | 12.4 per 1,000 likely 10.2 per 1,000 – 14.9 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 1,558 cases | Worse | 12.8 per 100 likely 11.3 per 100 – 14.4 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 1,558 cases | No different | 5 per 100 likely 4.2 per 100 – 6.1 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 1,196 cases | No different | 1 likely 0.8 – 1.3 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
1,880 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 742 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Internal Medicine | 203 |
| Anesthesiology | 121 |
| Hospitalist | 118 |
| Diagnostic Radiology | 71 |
| Neurology | 66 |
| Nurse Anesthetist, Certified Registered | 59 |
| Emergency Medicine | 56 |
| Nurse Practitioner | 55 |
| Clinical | 53 |
| Psychiatry | 52 |
| Gastroenterology | 51 |
| Adult Health | 49 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $20.6M
- 2020 $32.8M
- 2021 $28.4M
- 2022 $23.5M
- 2023 $21.4M
- 2024 $19.7M
- 2025 $21.5M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $1.8M | 32 |
| Grants | $568,662 | 23 |
| Medical devices and supplies on long-term loan | $177,844 | 25 |
| Consulting fees | $165,440 | 8 |
| Space rental and facility fees | $150,354 | 28 |
| Education | $115,000 | 2 |
| Speaking, teaching and other services | $89,030 | 11 |
| Charitable contributions | $5,000 | 2 |
| Gifts | $5,000 | 1 |
| Debt forgiveness | $2,121 | 8 |
| Food and beverage | $207 | 4 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Pfizer INC. | $4.8M | 55 |
| Merck Sharp & Dohme LLC | $2.8M | 10 |
| Ge Healthcare | $1.7M | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.5M | 196 |
| Vertex Pharmaceuticals Incorporated | $1.2M | 12 |
| Abbvie INC. | $1.1M | 59 |
| Regeneron Pharmaceuticals, Inc. | $704,751 | 94 |
| AstraZeneca Pharmaceuticals LP | $516,788 | 7 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| CRC COE A PHASE 2 EFFICACY AND SAFETY STUDY OF CIBINQO IN NONHOSPITALIZED LOWRISK ADULT PARTICIPANTS WITH POSTACUTE SEQUELAE OF SARSCOV2 INFECTION PFIZER INC. | $1.6M |
| A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants wi… Merck Sharp & Dohme LLC | $1.3M |
| PFIZERBAROUCH VACCINE MUCOSAL IMMUNITY COLLABORATION PFIZER INC. | $971,838 |
| A PHASE 1 STUDY OF VACCINATION WITH DENDRITIC CELL DCMULTIPLE MYELOMA MM FUSIONS IN COMBINATION WITH ELRANATAMAB IN RELAPSED OR REFRACTORY MULTIPLE M… PFIZER INC. | $925,786 |
| A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carci… Merck Sharp & Dohme LLC | $860,208 |
| Mechanisms of action of onabotulinumtoxinA ABBVIE INC. | $425,000 |
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjec… CSL Behring · NCT03473223 | $419,152 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTE… Takeda Pharmaceuticals U.S.A., Inc. · NCT04530123 | $374,161 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Beth Israel Deaconess Medical Center
Is Beth Israel Deaconess Medical Center a good hospital?
Beth Israel Deaconess Medical Center has a CMS overall rating of 3 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 7 and worse on 5. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Beth Israel Deaconess Medical Center?
79% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 5,505 completed HCAHPS surveys.
How long is the wait in the Beth Israel Deaconess Medical Center emergency room?
Emergency patients spend a median of 5 h 36 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Beth Israel Deaconess Medical Center receive money from drug and device companies?
Drug and device makers reported $21.5M in payments to Beth Israel Deaconess Medical Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.